
-
Ventyx Biosciences NasdaqGS:VTYX Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in Phase 2a trial for patients with early Parkinson's disease and is in Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Location: 12790 El Camino Real, Suite 250, San Diego, CA, 92130, United States | Website: https://ventyxbio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-89.46M
Cash
228.8M
Avg Qtr Burn
-27.24M
Short % of Float
11.09%
Insider Ownership
4.14%
Institutional Own.
68.47%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
VTX2735 (NLRP3 inhibitor) Details Recurrent Pericarditis | Phase 2 Data readout | |
VTX3232 Details Obesity and cardiometabolic risk factors | Phase 2 Data readout | |
Tamuzimod (VTX002) (S1P1R modulator) Details Ulcerative colitis | Phase 2 Update | |
VTX958 (TYK2 inhibitor) Details Crohns disease | Phase 2 Update | |
Phase 2a Data readout | ||
VTX958 (TYK2 inhibitor) Details Psoriatic arthritis, Psoriasis | Failed Discontinued |